References:
- Hashemi, Fallah, Lori Hoepner, FARAHNAZ Soleimani Hamidinejad, Daniela
Haluza, Sima Afrashteh, Alireza Abbasi, Elma Omeragić et al. ”A
Comprehensive Health Effects Assessment of the Use of Sanitizers and
Disinfectants during COVID-19 Pandemic: A Global Survey (preprint).”
(2022).
- Harfouch, R. M. ”Antiviral Effects of Propolis against SARS-COV 2.”Int J Clin Med Imaging 9 809 (2022).
- Harfouch, R. M., S. Alshaikh, M. Alshimaly, A. Assaad, J. Ahmad, H.
Zoughaibi, M. Hammadi, and Y. Elshimali. ”Therapeutic approaches for
covid 19: Challenges and successes.” Annals of Clinical and
Analytical Medicine (2021): 228-233.
- Alhouri, Ali, et al. ”Possible side effects of using detergents during
the Covid19 pandemic in Syria.” Ann. Clin. Cases 1.4 (2020):
1023.
- Harfouch, Rim M. ”Cytokine Storm syndrome in COVID-19 patients:
Characteristics And diagnosis.” Journal of Clinical Epidemiology
& Toxicology 2.4 (2021): 1-3.
- Harfouch, R. M., et al. ”Epidemiology of COVID-19 in the most pandemic
Countries: A review article. Acad.” J. Biotechnol 9.1 (2021):
021-027.
- Harfouch, Rim. ”Multiple organs failure in COVID-19 patients.”Authorea Preprints (2022).
- Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dube M,
et al. Human coronaviruses and other respiratory viruses:
underestimated opportunistic pathogens of the central nervous system?
Viruses. 2019;12(1)
- Harfouch, Rim. ”Effect of SARS-COV2 virus on nervous system and mental
health.” Authorea Preprints (2022).
- Matschke J, Lutgehetmann M, Hagel C, Sperhake JP, Schroder AS, Edler
C, et al. Neuropathology of patients with COVID-19 in Germany: a
post-mortem case series. Lancet Neurol. 2020;19(11):919–29.
- Jarius S, Pache F, Kortvelyessy P, Jelcic I, Stettner M, Franciotta D,
et al. Cerebrospinal fluid findings in COVID-19: a multicenter study
of 150 lumbar punctures in 127 patients. J Neuroinflammation.
2022;19(1):19.
- Coolen T, Lolli V, Sadeghi N, Rovai A, Trotta N, Taccone FS, et al.
Early postmortem brain MRI findings in COVID-19 non-survivors.
Neurology. 2020;95(14):e2016–27.
- Thakur KT, Miller EH, Glendinning MD, et al. COVID-19 neuropathology
at Columbia University Irving Medical Center/New York Presbyterian
Hospital. Brain. 2021;144:2696-2708.
- Lou JJ, Movassaghi, M & Gordy, D, et al. Neuropathology of COVID-19
(neuro-COVID): clinicopathological update. Free Neuropathol. 2021;Jan
18;2:2.
- Jiang T, Zhang Y-D, Zhou J-S, et al. Angiotensin-(1-7) is reduced and
inversely correlates with tau hyperphosphorylation in animal models of
Alzheimer’s disease. Mol Neurobiol. 2016;53:2489-2497.
- Kehoe PG, Wong S, Al Mulhim N, Palmer LE, Miners JS.
Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in
association with increasing amyloid-beta and tau pathology. Alzheimers
Res Ther. 2016;8:50.
- Leng F, Edison P. Neuroinflammation and microglial activation in
Alzheimer disease: where do we go from here? Nat Rev Neurol.
2021;17(3):157–72.
- Abate G, Memo M, Uberti D. Impact of COVID-19 on Alzheimer’s disease
risk: viewpoint for research action. Healthcare. 2020.
https://doi.org/10.3390
- Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines
released from microglia in Alzheimer’s disease. Ann Transl Med.
2015;3(10):136.
- Chen, F., Chen, Y., Wang, Y. et al. The COVID-19 pandemic and
Alzheimer’s disease: mutual risks and mechanisms. Transl
Neurodegener 11 , 40 (2022).
https://doi.org/10.1186/s40035-022-00316-y